Literature DB >> 3338303

Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus.

P G Wilcox1, H B Stein, S D Clarke, P D Paré, R L Pardy.   

Abstract

Diaphragmatic weakness has been identified as one of the pulmonary manifestations of systemic lupus erythematosus. Whether this weakness results from a neuropathic or myopathic process has not been established. Thirty patients with SLE were screened for the presence of inspiratory muscle (IM) weakness. Detailed studies were performed in nine with IM weakness. All nine were found to have diaphragmatic weakness (mean +/- SD, maximal transdiaphragmatic pressure 50 +/- 12 cmH2O). Phrenic nerve latencies, evaluated using transcutaneous stimulation, were normal in all individuals excluding a demyelinating neuropathy. Compound diaphragm action potential (CDAP) with phrenic nerve stimulation was normal in six of these nine patients. Reduced CDAP in three of nine patients was consistent either with axonal degeneration of the phrenic nerve or diaphragm myopathy. Nerve conduction and electromyographic studies on peripheral nerves and muscles respectively failed to demonstrate an associated generalized neuropathy or myopathy. We conclude that diaphragmatic weakness in patients with SLE is both common and is very unlikely to be caused by a phrenic neuropathy.

Entities:  

Mesh:

Year:  1988        PMID: 3338303     DOI: 10.1378/chest.93.2.352

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Diaphragmatic paresis: pathophysiology, clinical features, and investigation.

Authors:  G J Gibson
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

2.  Diaphragmatic paresis: pathophysiology, clinical features, and investigation.

Authors:  C M Laroche; M Green
Journal:  Thorax       Date:  1990-04       Impact factor: 9.139

Review 3.  Diaphragmatic weakness and paralysis.

Authors:  P G Wilcox; R L Pardy
Journal:  Lung       Date:  1989       Impact factor: 2.584

Review 4.  Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases.

Authors:  Débora Cerqueira Calderaro; Gilda Aparecida Ferreira
Journal:  Rheumatol Int       Date:  2011-03-23       Impact factor: 2.631

5.  Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.

Authors:  Alejandro Robles-Perez; Jordi Dorca; Ivan Castellví; Joan Miquel Nolla; Maria Molina-Molina; Javier Narváez
Journal:  Rheumatol Int       Date:  2020-03-10       Impact factor: 2.631

6.  The "shrinking lung syndrome" in SLE, treatment with theophylline.

Authors:  S Van Veen; A J Peeters; P J Sterk; F C Breedveld
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

7.  Respiratory disease in systemic lupus erythematosus: correlation with results of laboratory tests and histological appearance of muscle biopsy specimens.

Authors:  S A Evans; N D Hopkinson; W J Kinnear; L Watson; R J Powell; I D Johnston
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

Review 8.  Shrinking lung syndrome masked by pleuropericarditis: a case report and review of the literature.

Authors:  Iman Hemmati; Kenneth Blocka
Journal:  Clin Rheumatol       Date:  2012-08-26       Impact factor: 2.980

9.  Shrinking lung syndrome in systemic lupus erythematosus-scleroderma overlap.

Authors:  Vivek S Guleria; Pradeep K Singh; Puneet Saxena; Shankar Subramanian
Journal:  Lung India       Date:  2014-10

Review 10.  Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.

Authors:  Helena Borrell; Javier Narváez; Juan José Alegre; Ivan Castellví; Francesca Mitjavila; María Aparicio; Eulàlia Armengol; María Molina-Molina; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.